Memantine Hydrochloride
Product Images NDC 62980-122

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 62980-122). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Vivimed Labs Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (B2acbf19 563c 4995 8ef5 0cee182f2cdf 01)

Chemical structure of Memantine Hydrochloride showing a cage-like amine structure with NH2 and HCl groups and methyl substituents.*

FDA Label Image

Figure 1 (B2acbf19 563c 4995 8ef5 0cee182f2cdf 02)

A line graph comparing the mean change from baseline in ADCS-ADL score over 28 weeks of treatment between placebo and Memantine Hydrochloride (Memantine HCl). The graph shows two lines with error bars, indicating clinical improvement above the baseline and clinical decline below it. One line represents placebo, showing a greater decline over time, while the other represents Memantine HCl, showing less decline during the treatment period.*

FDA Label Image

Figure 2 (B2acbf19 563c 4995 8ef5 0cee182f2cdf 03)

A cumulative percentage of patients chart showing ADCS-ADL change from baseline on the x-axis and cumulative percentage on the y-axis. The graph compares placebo and Memantine Hydrochloride groups, indicating differences in patient response distributions between the two.*

FDA Label Image

Figure 3 (B2acbf19 563c 4995 8ef5 0cee182f2cdf 04)

A line graph comparing the mean change from baseline in SIB Score over 28 weeks of treatment between Placebo and Memantine Hydrochloride (Memantine HCl). The y-axis measures the mean ± SEM change, indicating clinical improvement or decline, while the x-axis shows weeks of treatment from 0 to 28. Data points include error bars.*

FDA Label Image

Figure 4 (B2acbf19 563c 4995 8ef5 0cee182f2cdf 05)

A line graph comparing the cumulative percentage of patients over SIB change from baseline for Memantine Hydrochloride and placebo. The x-axis represents SIB change from baseline, and the y-axis shows the cumulative percentage of patients. Two lines are plotted: one with circles for Memantine HCl and another with squares for placebo, illustrating patient response differences.*

FDA Label Image

Figure 5 (B2acbf19 563c 4995 8ef5 0cee182f2cdf 06)

A line graph displaying the mean change from baseline in ADCS-ADL Score over 24 weeks of treatment. Two groups are shown: Placebo/Donepezil and Memantine HCl/Donepezil. The graph includes error bars (± SEM) for each data point. The vertical axis shows the score change, with clinical improvement and clinical decline noted, and the horizontal axis shows the week of treatment.*

FDA Label Image

Figure 6 (B2acbf19 563c 4995 8ef5 0cee182f2cdf 07)

A cumulative percentage curve chart showing patient response to treatment based on ADCS-ADL change from baseline. It compares two groups: one receiving MEMANTINE HCl/Donepezil and the other receiving Placebo/Donepezil, with the MEMANTINE HCl/Donepezil group showing a higher cumulative percentage of patients improving.*

FDA Label Image

Figure 7 (B2acbf19 563c 4995 8ef5 0cee182f2cdf 08)

A line graph showing mean change in SIS score from baseline over 24 weeks of treatment comparing Memantine Hydrochloride/Donepezil versus Placebo/Donepezil. The x-axis represents weeks of treatment, and the y-axis represents mean change with error bars. Memantine HCl/Donepezil shows clinical improvement, while Placebo/Donepezil trends toward clinical decline.*

FDA Label Image

Figure 8 (B2acbf19 563c 4995 8ef5 0cee182f2cdf 09)

A cumulative percentage graph comparing the change in SIB (Severe Impairment Battery) scores from baseline between two patient groups: one treated with Placebo/Donepezil and the other with Memantine Hydrochloride/Donepezil. The x-axis shows SIB change from baseline, and the y-axis shows cumulative percentage of patients, illustrating differences in patient response distributions.*

FDA Label Image

Label (B2acbf19 563c 4995 8ef5 0cee182f2cdf 10)

Memantine Hydrochloride Tablets USP 5 mg label displaying the NDC number 64679-121-03. The label indicates prescription-only status, instructs pharmacists to provide a patient information leaflet separately, and states the package contains 60 tablets. The labeler is Wockhardt, with a logo visible at the bottom.*

FDA Label Image

Label (B2acbf19 563c 4995 8ef5 0cee182f2cdf 11)

Label for Memantine Hydrochloride Tablets, USP 10 mg. The label shows a package size of 60 tablets and includes a note that the product is Rx only. The label also mentions dispensing with a patient information leaflet and features the Wockhardt logo at the bottom.*

FDA Label Image

Label 10 mg -500t (B2acbf19 563c 4995 8ef5 0cee182f2cdf 12)

Label of Memantine Hydrochloride Tablets, USP 10 mg by Wockhardt, showing NDC 64679-122-02. It indicates a prescription-only medication with a package count of 500 tablets and includes a pharmacist note to dispense with a patient information leaflet.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.